Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.50 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.38 |
| ▸ | GLRB | P48167 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8678918 | 0.86 | GABRA1 (0.50) | CA2GABRA1GABRB2HSPA5LMNA | |
| SCHEMBL10597480 | 0.85 | CA2 (0.45) | CA2GABRA1GABRB2HSPA5CA1 | |
| SCHEMBL23940954 | 0.85 | CA2 (0.45) | CA2GABRA1GABRB2HSPA5CA1 | |
| SCHEMBL430925 | 0.85 | CA2 (0.45) | CA2GABRA1GABRB2HSPA5CA1 | |
| SCHEMBL6404761 | 0.84 | HSPA5 (0.44) | CA2GABRA1GABRB2HSPA5CA1 | |
| SCHEMBL14830878 | 0.83 | GABRA1 (0.46) | CA2GABRA1GABRB2HSPA5CA1 | |
| SCHEMBL12943015 | 0.83 | GABRA1 (0.46) | CA2GABRA1GABRB2HSPA5SMN1; SMN2 | |
| SCHEMBL47580 | 0.83 | CA2 (0.68) | CA2GABRA1GABRB2HSPA5CA1 | |
| SCHEMBL45861 | 0.83 | GABRA1 (0.68) | GABRA1GABRB2HSPA5TYRALOX15 | |
| SCHEMBL30938109 | 0.83 | CA2 (0.68) | CA2GABRA1GABRB2HSPA5CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040924-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | ALLACCEM, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8153618-B2 | Bridged polycyclic compound based compositions for topical applications for pets | ALLACCEM, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-7713955-B2 | Applying to a surface one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning | ALLACCEM, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100016270-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS | ALLACCEM, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20090069435-A1 | Bridged polycyclic compound based compositions for topical applications for pets | ALLACCEM, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090054528-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | ALLACCEM, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20080207581-A1 | Applying to a surface one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning | ALLACCEM, INC. | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069435-A1 | Bridged polycyclic compound based compositions for topical applications for pets | OTC, SLC16A8, SLC16A7 | CA2 96/4885GABRA1 2969/4885GABRB2 2640/4885 |
| US-20090054528-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | PAICS, SLC16A8, CAD | CA2 55/4885GABRA1 1494/4885GABRB2 2798/4885 |
| US-20100016270-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS | PCSK9, HMGCR, CETP | CA2 981/4885GABRA1 4259/4885GABRB2 4325/4885 |
| US-20130040924-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | PKD1, VHL, PKD2 | CA2 212/4885GABRA1 3607/4885GABRB2 3467/4885 |
| US-20080207581-A1 | Applying to a surface one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning | DNMT1, TET2, CD14 | CA2 479/4885GABRA1 2552/4885GABRB2 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.